MEGAN DEGORI: Open Payments
NPI 1457752081 · STEUBENVILLE, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,113 in 166 payments from 19 companies in 2025. Trend: 2023 $2,644 · 2024 $3,022 · 2025 $3,113
Food & beverage: $3,113
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $723 |
| Madrigal Pharmaceuticals | 31 | $667 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 32 | $442 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $286 |
| Phathom Pharmaceuticals, Inc. | 8 | $185 |
| Gilead Sciences, Inc. | 11 | $163 |
| Ardelyx, Inc. | 6 | $106 |
| Novo Nordisk Inc | 5 | $97 |
| Ipsen Biopharmaceuticals, Inc | 5 | $79 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
Products named: REZDIFFRA, XIFAXAN, ENTYVIO, CREON, VOQUEZNA, RINVOQ, LINZESS, IBSRELA.
Industry payments across OH — which companies pay providers there.
